DK2993983T3 - Målretningskorroler til tumortoksicitet og mri - Google Patents

Målretningskorroler til tumortoksicitet og mri Download PDF

Info

Publication number
DK2993983T3
DK2993983T3 DK14794410.2T DK14794410T DK2993983T3 DK 2993983 T3 DK2993983 T3 DK 2993983T3 DK 14794410 T DK14794410 T DK 14794410T DK 2993983 T3 DK2993983 T3 DK 2993983T3
Authority
DK
Denmark
Prior art keywords
mri
target directions
tumor toxicity
toxicity
tumor
Prior art date
Application number
DK14794410.2T
Other languages
Danish (da)
English (en)
Inventor
Lali K Medina-Kauwe
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Application granted granted Critical
Publication of DK2993983T3 publication Critical patent/DK2993983T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK14794410.2T 2013-05-08 2014-05-08 Målretningskorroler til tumortoksicitet og mri DK2993983T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361821106P 2013-05-08 2013-05-08
PCT/US2014/037234 WO2014182868A1 (en) 2013-05-08 2014-05-08 Targeting corroles for tumor toxicity and mri

Publications (1)

Publication Number Publication Date
DK2993983T3 true DK2993983T3 (da) 2020-05-18

Family

ID=51864925

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14794410.2T DK2993983T3 (da) 2013-05-08 2014-05-08 Målretningskorroler til tumortoksicitet og mri

Country Status (16)

Country Link
US (2) US9757386B2 (enExample)
EP (2) EP2993983B1 (enExample)
JP (1) JP6640715B2 (enExample)
KR (1) KR20160008523A (enExample)
CN (2) CN105307499B (enExample)
AU (2) AU2014262653B2 (enExample)
CA (1) CA2910030A1 (enExample)
DK (1) DK2993983T3 (enExample)
ES (1) ES2791043T3 (enExample)
IL (1) IL265935B (enExample)
MX (1) MX2015015434A (enExample)
PL (1) PL2993983T3 (enExample)
PT (1) PT2993983T (enExample)
RU (1) RU2674146C2 (enExample)
WO (1) WO2014182868A1 (enExample)
ZA (1) ZA201508092B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009009441A2 (en) 2007-07-06 2009-01-15 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
JP6618360B2 (ja) 2012-08-03 2019-12-11 セダーズ−シナイ メディカル センター 薬物送達タンパク質の輸送向上変異体の単離
RU2674146C2 (ru) 2013-05-08 2018-12-07 Седарс-Синай Медикал Центр Нацеленные корролы, проявляющие опухолевую токсичность и предназначенные для мрт
WO2015109264A1 (en) 2014-01-17 2015-07-23 Cedars-Sinai Medical Center Receptor targeting constructs and uses thereof
JP6728056B2 (ja) 2014-04-04 2020-07-22 シーダーズ—シナイ メディカル センター Her3標的ナノ粒子によりトラスツズマブ耐性her2+乳癌を標的にすること
WO2019043711A1 (en) * 2017-08-31 2019-03-07 Technion Research & Development Foundation Limited COMPOSITIONS OF CORROLE

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA129822A (en) 1910-08-24 1910-12-13 The John Bertram And Sons Company, Limited Motor controlling apparatus
CA140995A (en) 1912-03-05 1912-06-11 Davydd C. Hughes Type plate mechanism
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
WO2002094318A1 (en) 2001-05-18 2002-11-28 University Of Southern California Vector for targeted delivery to cells
DE60236870D1 (de) * 2001-07-02 2010-08-12 Technion Res & Dev Foundation Verfahren zur herstellung selektiv substituierter corrole und neue substituierte corrole
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
WO2009009441A2 (en) 2007-07-06 2009-01-15 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
WO2009027965A1 (en) 2007-08-28 2009-03-05 Technion Research And Development Foundation Ltd. Transition metal complexes of corroles for preventing cardiovascular diseases or disorders
US20110098262A1 (en) * 2008-01-31 2011-04-28 Yondim Moussa B H Corroles for neuroprotection and neurorescue
WO2009151539A1 (en) 2008-05-24 2009-12-17 Sirnaomics, Inc. COMPOSITIONS AND METHODS USING siRNA MOLECULES FOR TREATMENT OF GLIOMAS
WO2010078517A2 (en) 2008-12-31 2010-07-08 Sirnaomics, Inc. Compositions and methods using sirna molecules and sirna cocktails for the treatment of breast cancer
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
CN101704820A (zh) * 2009-09-24 2010-05-12 江苏大学 三(4-氯苯基)咔咯化合物及其合成方法
WO2011094335A2 (en) 2010-01-26 2011-08-04 Yale University Microrna signatures predicting responsiveness to anti-her2 therapy
MX2014001823A (es) * 2011-08-15 2014-08-21 Technion Res & Dev Foundation Combinaciones de corroles y estatinas.
JP6618360B2 (ja) 2012-08-03 2019-12-11 セダーズ−シナイ メディカル センター 薬物送達タンパク質の輸送向上変異体の単離
RU2674146C2 (ru) 2013-05-08 2018-12-07 Седарс-Синай Медикал Центр Нацеленные корролы, проявляющие опухолевую токсичность и предназначенные для мрт
WO2015109264A1 (en) 2014-01-17 2015-07-23 Cedars-Sinai Medical Center Receptor targeting constructs and uses thereof
JP6728056B2 (ja) 2014-04-04 2020-07-22 シーダーズ—シナイ メディカル センター Her3標的ナノ粒子によりトラスツズマブ耐性her2+乳癌を標的にすること
AU2017271662A1 (en) 2016-05-27 2018-12-06 Cedars-Sinai Medical Center Drug-delivery nanoparticles and treatments for drug-resistant cancer

Also Published As

Publication number Publication date
CA2910030A1 (en) 2014-11-13
AU2018250401B2 (en) 2020-06-11
CN105307499A (zh) 2016-02-03
CN105307499B (zh) 2018-04-27
HK1221870A1 (en) 2017-06-16
AU2018250401A1 (en) 2018-11-08
KR20160008523A (ko) 2016-01-22
RU2015152033A (ru) 2017-06-16
EP2993983A4 (en) 2017-01-11
PT2993983T (pt) 2020-05-22
EP2993983B1 (en) 2020-03-25
JP2016526021A (ja) 2016-09-01
RU2674146C2 (ru) 2018-12-07
US20170281802A1 (en) 2017-10-05
IL265935A (en) 2019-05-30
WO2014182868A1 (en) 2014-11-13
ES2791043T3 (es) 2020-10-30
MX2015015434A (es) 2016-03-15
US20140335025A1 (en) 2014-11-13
US10709801B2 (en) 2020-07-14
CN108451930A (zh) 2018-08-28
EP3730155A1 (en) 2020-10-28
AU2014262653B2 (en) 2018-07-26
AU2014262653A1 (en) 2015-11-12
EP2993983A1 (en) 2016-03-16
PL2993983T3 (pl) 2020-09-07
JP6640715B2 (ja) 2020-02-05
RU2015152033A3 (enExample) 2018-04-25
ZA201508092B (en) 2017-02-22
IL265935B (en) 2020-06-30
US9757386B2 (en) 2017-09-12

Similar Documents

Publication Publication Date Title
IL255312A0 (en) Therapeutic and diagnostic methods for cancer
EP3463072A4 (en) SURGICAL MAGNETOMETER.
DK2970896T3 (da) Manipulerede levervæv, arrays deraf og fremgangsmåder til fremstilling heraf
DK3888658T3 (da) Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil
DK3043784T3 (da) Arylethere og anvendelser deraf
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK2956483T3 (da) Terapeutisk og diagnostisk mål for cancer omfattende dll3-bindende reagenser
DK3052181T3 (da) Mikronåleplastre og systemer
HUE057061T2 (hu) Kombinációs terápia rák kezelésére
IL245036B (en) Pesticidal compositions and related methods
DK3381917T3 (da) Imidazopyridinforbindelser og anvendelser deraf
DK3052485T3 (da) Heterocykliske forbindelser og anvendelser deraf
DK3356558T3 (da) Sirs patogenbiomarkører og anvendelser deraf
DK3003039T3 (da) Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser
DK3063144T3 (da) Antiparasitære og pesticid-isoxazolinforbindelser
DK3079719T3 (da) ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf
DK2970123T3 (da) Salt af omecamtiv mecarbil og fremgangsmåde til fremstilling heraf
DK3076976T3 (da) Fremgangsmåder til behandling af cancer
IL253160B (en) Cancer markers and methods of use thereof
EP2967478A4 (en) ON THE BODY PORTABLE ELECTROMAGNETIC TOMOGRAPHIC IMAGING
DK2964767T3 (da) Toksingener og fremgangsmåder til anvendelse deraf
DK2962100T3 (da) Tuberkulosebiomarkører og anvendelser deraf
DK3030549T3 (da) Pyridazinonforbindelser og anvendelser deraf
KR101900491B9 (ko) 자기장 치료기
DK3027564T3 (da) Nedsænket forbrændingssmelter og fremgangsmåde